Medindia

X

Association Between Interleukin 17F Level and Interferon Beta Response in Patients With Multiple Sclerosis

by Bidita Debnath on  June 6, 2013 at 5:16 PM Research News   - G J E 4
A study examines the association between IL-17F and treatment response to interferon beta-1b among patients with relapsing-remitting multiple sclerosis. (Online First)

The study was done by by Hans-Peter Hartung, M.D., of Heinrich-Heine-University, Dusseldoft, Germany, and colleagues.
 Association Between Interleukin 17F Level and Interferon Beta Response in Patients With Multiple Sclerosis
Association Between Interleukin 17F Level and Interferon Beta Response in Patients With Multiple Sclerosis
Advertisement

Serum samples were analyzed with an immunoassay from 239 randomly selected patients treated with interferon beta-1b, 250 micrograms, for at least 2 years in the Betaferon Efficacy Yielding Outcomes of a New Dose Study. Researchers measured the levels of IL-17F at baseline and month 6, as well as the difference between the IL-17F levels at month 6 and baseline were compared between: (1) patients with less disease activity versus more disease activity; (2) patients with no disease activity versus some disease activity; and (3) responders versus nonresponders.

Advertisement
According to study results, levels of IL-17F measured at baseline and month 6 did not correlate with lack of response to treatment after 2 years using clinical and magnetic resonance imaging (MRI) criteria. Relapses and new lesions on MRI were not associated with pretreatment serum IL-17F levels. When patients with neutralizing antibodies were excluded, the results did not change.

"We found that serum concentrations of IL-17F alone did not predict response to interferon beta-1b therapy in patients with relapsing-remitting multiple sclerosis." The study concludes, "Given the multifaceted pathophysiology associated with disease progression and response to treatment by patients with relapsing-remitting multiple sclerosis, using extreme patient cohorts in combination with immune-based biomarker signatures may actually be the most efficient way of initially identifying response markers."
(JAMA Neurol. Published online June 3, 2013. doi:10.1001/.jamaneurol.2013.192. Available pre-embargo to the media at http://media.jamanetwork.com.)

Source: Newswise
Advertisement

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
Notify me when reply is posted I agree to the terms and conditions

You May Also Like

Advertisement
View All